Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study

被引：0
|
作者：
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
De Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De la Mora
Zhou, Jianying
Perol, Maurice
Lee, Hyeong
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[3] Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Ist Europeo Oncol, Milan, Italy
[7] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Med Sur Hosp, Ctr Oncol, Mexico City, Mexico
[10] Peking Union Med Coll Hosp, Beijing, Peoples R China
[11] Chang Gung Mem Hosp, Taoyuan, Taiwan
[12] Inst Jalisciense Cancerol, Guadalajara, Mexico
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Ctr Leon Berard, Lyon, France
[15] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[16] Hosp Univ Virgen Macarena, Seville, Spain
[17] Okayama Univ Hosp, Okayama, Japan
[18] Mem Sloan Kettering Canc Ctr, New York, NY USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9000
引用
收藏
页数：1
相关论文
共 50 条
  • [11] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [12] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
    Rodriguez-Abreu, D.
    Powell, S. F.
    Hochmair, M. J.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    De Angelis, F.
    Domine, M.
    Cheng, S. Y.
    Bischoff, H. G.
    Peled, N.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Kurata, T.
    Yang, J.
    Pietanza, M. C.
    Souza, F.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2021, 32 (07) : 881 - 895
  • [13] First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI
    Husain, H.
    Martins, R. G.
    Goldberg, S. B.
    Senico, P.
    Ma, W.
    Masters, J.
    Pathan, N.
    Kim, D-W.
    Socinski, M. A.
    Goldberg, Z.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [14] RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
    Saltos, A.
    Baik, C.
    Sanborn, R. E.
    Shum, E.
    Kim, C.
    Hall, R.
    Fidler, M. J.
    Shu, C. A.
    Otterson, G.
    Patel, J.
    Wong, K.
    Hanna, N.
    Gray, J.
    Heymach, J.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S614 - S614
  • [15] An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
    Le, X.
    Zhu, V.
    Saltos, A.
    Nikolinakos, P.
    Mileham, K.
    Velcheti, V.
    Husain, H.
    Nilsson, M.
    Tran, H.
    Roarty, E.
    Kim, E.
    Ou, S.
    Sanborn, R.
    Gray, J. E.
    Wong, K.
    Hanna, N.
    Papadimitrakopoulou, V.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S838 - S838
  • [16] The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
    Gray, Jhanelle E.
    Schenker, Michael
    Sendur, Mehmet Ali Nahit
    Leonova, Viktoriya
    Kowalski, Dariusz
    Kato, Terufumi
    Orlova, Rashida
    Yang, James Chih-Hsin
    Langleben, Adrian
    Pilz, Arnold
    Ungureanu, Andrei
    Mak, Milena Perez
    De Angelis, Flavia
    Aggarwal, Himani
    Zimmer, Zachary
    Zhao, Bin
    Shamoun, Mark
    Kim, Tae Min
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 219 - 232
  • [17] KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
    Rodriguez Abreu, D.
    Garassino, M. C.
    Esteban, E.
    Speranza, G.
    Felip, E.
    Domine, M.
    Hochmair, M. J.
    Powell, S.
    Cheng, S. Y-S.
    Bischoff, H. G.
    Peled, N.
    Hui, R.
    Reck, M.
    Garon, E. B.
    Boyer, M.
    Grossi, F.
    Jennens, R.
    Yang, J.
    Pietanza, M. C.
    Gadgeel, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 164 - 164
  • [18] KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
    Rodriguez Abreu, D.
    Garassino, M. C.
    Esteban, E.
    Speranza, G.
    Felip, E.
    Domine, M.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y-S.
    Bischoff, H.
    Peled, N.
    Hui, R.
    Reck, M.
    Garon, E. B.
    Boyer, M.
    Grossi, F.
    Jennens, R.
    Yang, J.
    Pietanza, M. C.
    Gadgeel, S. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [19] A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
    Wu, S-G.
    Ho, C-C.
    Yang, J. C.
    Liao, B-C.
    Yang, C-Y.
    Lin, Y-T.
    Yu, C-J.
    Liao, W-Y.
    Shih, J-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S33 - S34
  • [20] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345